

Residual Serum Fibrinogen as a Universal Biomarker for all Serotypes of Myasthenia Gravis

Faraz S. Hussain¹, Ramanaguru S. Piragasam², Hassan Sarker², Derrick Blackmore¹, Elaine Yacyshyn³, Carlos Fernandez-Patron², Richard P. Fahlman^{2,*} & Zaeem A. Siddiqi^{1,*}.

¹ Division of Neurology, Department of Medicine, Faculty of Medicine & Dentistry, University of Alberta.

² Department of Biochemistry, Faculty of Medicine & Dentistry, University of Alberta.


³ Division of Rheumatology, Department of Medicine, Faculty of Medicine & Dentistry, University of Alberta.

*To whom correspondence should be addressed: zsiddiqi@ualberta.ca or rfahlman@ualberta.ca


Supplemental Data

Supplemental Information in the forms of Supplemental Tables are attached in Microsoft office Excel. Supplemental Table 1: Raw data – extracted ion intensities; Supplemental Table 2: Corrected data – normalized data; Supplemental Table 3: ANOVA – analysis of variance; Supplemental Table 4: PRM ion lists – parallel reaction monitoring peptide and transition ion list; Supplemental Table 5: PRM data – raw parallel reaction monitoring data.


Supplementary Data: Uncropped Blot Images for Review Process




Supplementary Figure S1: This is the uncropped image for the Figure 2a (*Upper Blot*), representing western blot analysis for total protein loading




Supplementary Figure S2: This is the uncropped image for the Figure 2a (*Middle Blot*), representing western blot analysis for Fibrinogen- α C-terminal (specific to 750-850 residues)




Supplementary Figure S3: This is the uncropped image for the Figure 2a (*Lower Blot*), representing western blot analysis for Fibrinogen- α N-terminal (specific to 21-320 residues)




Supplementary Figure S3: This is the uncropped image for the Figure 2b, representing western blot analysis for Fibrinogen- α in plasma




Supplementary Figure S4: This is the uncropped image for the Figure 2c, a comparative analysis of Fibrinogen- α in both plasma and serum



Supplementary Figure S5: This is the uncropped image Figure 2e, representing stability of residual Fibrinogen- α after initial processing



Supplementary Figure S6: This is the uncropped image Figure 3 (Upper Blot), representing the blinded Investigation of MG serum samples



Supplementary Figure S7: This is the uncropped image Figure 3 (Lower Blot), representing the blinded Investigation of MG serum samples